Huaota is pleased to announce that Project HOT-1030 has been recently approved for drug clinical trial by the National Medical Products Administration.

HOT-1030 is a monoclonal antibody targeting CD137 (4-1BB), intended for the treatment of advanced malignant solid tumors. CD137, also known as 4-1BB, is a member of the tumor necrosis factor receptor superfamily (Tumor Necrosis Factor Receptor Superfamily 9, TNFRSF9), mainly expressed in activated T cells, NK cells, dendritic cells and other tumor immune cells. The ligand CD137L is mainly expressed in activated APCs while T cells express 4-1BB transiently after activation.